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Background: A major barrier to effective treatment of glioblastoma multiforme (GBM) is the invasion of glioma
cells into the brain parenchyma rendering local therapies such as surgery and radiation therapy ineffective. GBM
patients with such highly invasive and infiltrative tumors have poor prognosis with a median survival time of only
about a year. However, the mechanisms leading to increased cell migration, invasion and diffused behavior of
glioma cells are still poorly understood.
Methods: In the current study, we applied quantitative proteomics for the identification of differentially expressed
proteins in GBMs as compared to non-malignant brain tissues.
Results: Our study led to the identification of 23 proteins showing overexpression in GBM; these include
membrane proteins, moesin and CD44. The results were verified using Western blotting and immunohistochemistry
in independent set of GBM and non-malignant brain tissues. Both GBM tissues and glioma cell lines (U87 / U373)
demonstrated membranous expression of moesin and CD44, as revealed by immunohistochemistry and
immunofluorescence, respectively. Notably, glioma cells transfected with moesin siRNA displayed reduced migration
and invasion on treatment with hyaluronan (HA), an important component of the extracellular matrix in GBM.
CD44, a transmembrane glycoprotein, acts as a major receptor for hyaluronan (HA). Using co-immunoprecipitation
assays, we further demonstrated that moesin interacts with CD44 in glioma cells only after treatment with HA; this
implicates a novel role of moesin in HA-CD44 signaling in gliomas.
Conclusions: Our results suggest that development of inhibitors which interfere with CD44-moesin interactions
may open a new avenue in the future to mitigate cellular migration in gliomas.
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Glioblastoma multiforme (GBM) is the most common
primary adult brain tumor and is almost always lethal
due to persistent local recurrence and invasion into the
surrounding tissue. Malignant gliomas are highly inva-
sive and infiltrative tumors that have a poor prognosis
with a median survival of only about one year [1,2]. The
Canadian Cancer Society estimates an incidence rate of
2,800 new cases of brain cancer and 1,850 deaths from it
in Canada for the year 2012 [3]. A major barrier to ef-
fective treatment of GBM patients is invasion of cancer* Correspondence: kwmsiu@yorku.ca
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reproduction in any medium, provided the orcells into the brain parenchyma, rendering local therapies
such as surgery and radiation therapy ineffective. How-
ever, the mechanisms leading to increased cell invasion
and diffused behavior of glioma cells are still unclear [3,4].
Hyaluronan (HA), a principal glycosaminoglycan (GAG)
and an important component of the extracellular matrix
(ECM), is involved in the development, proliferation,
migration, invasion and therapeutic resistance observed in
cancer cells [5,6]. Higher amounts of HA have been
reported in ECM of GBM patients than that in normal
brain tissue. Abundant amounts of HA in gliomas have
been associated with poor prognosis in GBM patients
[5,6]. Thus, identification of the proteins and their roles
within this niche may lead to better understanding of the
behavior of glioma cells and provide a basis foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proliferation.
Recently, high-throughput quantitative proteomic
analysis using isobaric tags for relative and absolute
quantitation (iTRAQ) in combination with liquid
chromatography-tandem mass spectrometry (LC-MS/
MS) has been applied to the discovery of potential can-
didate markers for a variety of malignancies [7-13]. Such
studies have included our own reports on endometrial
carcinoma (EmCa), head and neck squamous cell car-
cinoma (HNSCC), oral premalignant lesions (OPL), and
renal cell carcinoma (RCC) [7-13]. In the current study,
we applied a similar approach for identification of pro-
teins and protein-protein interaction networks that may
be responsible for the highly invasive and lethal nature
of GBMs. Our study reveals 57 differentially expressed
proteins (23 upregulated and 34 downregulated) in
GBM tissue samples as compared to non-malignant
brain tissues. Importantly, we observe in GBM tissues
the overexpression of moesin, a member of the ERM
(ezrin, radixin, moesin) family of proteins, and CD44, an
important HA-receptor on cell membrane. The ERM
family of proteins functions as molecular cross-linkers
between plasma membrane receptors and cytoplasmic
actin filaments [14]. Notably in our iTRAQ analysis,
moesin shows overexpression while both ezrin and radixin
show no significant differential expression in GBMs in
comparison to non-malignant brain tissue samples. CD44
is a multifunctional, transmembrane glycoprotein showing
overexpression in a variety of malignancies and serves as
the major receptor for hyaluronan (HA). The HA-CD44
interaction potentially mediates invasion, migration, and
resistance to chemotherapy in several malignancies [15,16].
However, the mechanisms underlying HA-CD44 induced
migration, invasion and therapeutic resistance in gliomas is
poorly understood. This provided us the impetus to exam-
ine the role played by moesin, downstream of HA-CD44
signaling in glioma cells.
Results
Identification of differentially expressed proteins using
quantitative proteomics
Tissues lysates prepared from GBM and non-malignant
brain tissues were labeled with respective iTRAQ labels
for the identification and quantification of differentially
expressed proteins (Additional file 1: Table S1). Using
the 0.1% global FDR as cutoff, analysis of the two runs
of each set led to identification of 422 proteins in the
first set, 331 in the second set, and 310 in the third set.
In total, 753 non-redundant proteins were identified
across all three sets (see Additional file 2: Table S2). Pro-
teins that displayed expression levels altered by more
than 50% in at least three out of the six GBMs in com-
parison to both non-malignant brain tissue samples wereconsidered as differentially expressed. Following these cri-
teria, only 57 of 753 identified proteins were considered
differential expression in GBM. Of these, 23 proteins were
upregulated, while 34 proteins were downregulated
(Table 1). An ERM protein, moesin; stem cell markers,
CD44 and nestin; and calcium-binding proteins of the
S100 family, S100A11 and S100A6 were upregulated in
GBM tissues. Moesin overexpression was observed in all
six GBM tissues, while CD44 overexpression was observed
in four of six GBM tissues (Table 1). Intriguingly, three of
the seven isoforms of the 14-3-3 family, including 14-3-3
zeta, gamma, epsilon, and metabolic enzymes such as
gamma enolase were downregulated (Table 1).
Verification of differentially expressed proteins using
western blotting and immunohistochemistry (IHC)
Tissues lysates from an independent set of GBM (n = 3)
and non-malignant brain tissues (n = 2) were used for
Western blotting to confirm differential expression of
CD44, moesin, S100A11, 14-3-3ζ and γ-enolase. West-
ern blot analysis showed overexpression of moesin,
CD44 and S100A11 in at least two of the three GBM tis-
sues (GBM1 and GBM3) as compared to non-malignant
brain tissues (NB1 and NB4, Figure 1A). Further, both
14-3-3ζ and γ-enolase showed lower expression in GBM
tissues as compared to non-malignant brain tissues,
thereby verifying our iTRAQ data (Figure 1A). The results
for moesin and CD44 overexpression were further verified
in a second independent set of paraffin-embedded sec-
tions of GBM tissues (n = 15) using IHC. Twelve of 15
GBM samples showed strong moesin expression on the
membrane of glioma cells, while eight of 15 cases showed
strong membranous CD44 expression (Figure 1B). In each
tissue microarray used in this study, liver sections were
used as positive controls. In liver sections, both CD44 and
moesin showed faint cytoplasmic and moderate to strong
membranous immunostaining for moesin and CD44 (data
not shown). In negative controls, no immunostaining was
observed in either cytoplasm / membrane in glioma cells
(data not shown).
Effect of HA-treatment on migration, proliferation and
cell cycle in glioma cells
Our IHC results revealed an exclusive strong membran-
ous expression of both CD44 and moesin in glioma cells
in paraffin-embedded sections of GBM tissues. As CD44
is a receptor for hyaluronan (HA), and was identified
and verified as overexpressed in GBM tissues, we ex-
plored the effects of HA-treatment on cell migration,
proliferation, and cell cycle in glioma cells (U87 / U373)
as well as normal human astrocytes (NHA). Both, glioma
cells and NHA were treated with HA (50 – 100 μg/mL)
for up to 48 h to determine the effect of treatment on cell
migration using wound-healing assays. Wound closure
Table 1 List of differentially expressed proteins in GBM and non-malignant brain tissue samples
Accession # Name NB1 NB4 NB5 GBM1 GBM2 GBM3 GBM4 GBM5 GBM6
sp|P21333-2 Isoform 2 of filamin-A 1.46 1.37 0.33 5.20 7.24 3.31 7.80 7.66 7.87
sp|Q15084 Protein disulfide-isomerase A6 1.29 0.23 1.10 2.51 2.07 2.61 1.91 1.92 1.57
sp|P04792 Heat shock protein beta-1 0.95 0.96 1.45 6.19 2.78 2.47 2.96 1.80 2.33
sp|P04083 Annexin A1 1.06 0.86 1.96 3.63 1.61 3.31 3.47 30.48 28.31
sp|P06703 Protein S100-A6 0.94 1.04 2.03 10.86 4.06 9.73 3.53 6.03 10.47
sp|P26038 Moesin 1.29 1.04 1.51 2.65 2.03 2.54 4.74 4.70 12.36
sp|P16070 CD44 antigen 1.09 5.97 5.30 5.75 7.59 15.00
sp|P48681 Nestin 1.05 0.42 2.78 9.64 2.17 11.59 2.70 8.47 6.14
sp|P27797 Calreticulin 4.79 1.21 1.24 11.38 20.32 9.64 18.20 17.22 8.47
sp|P08758 Annexin A5 0.79 0.33 9.91 5.97 0.67 7.45 2.70 24.43 12.02
sp|P13667 Protein disulfide-isomerase A4 0.87 0.82 0.68 1.67 0.92 1.92 0.79 4.13 2.09
sp|P23284 Peptidyl-prolyl cis-trans isomerase B 0.69 0.80 7.38 8.55 12.82 4.61
sp|P17931 Galectin-3 0.96 1.07 9.73 12.02 2.61 1.75
sp|Q05682 Caldesmon 1.11 0.96 2.29 1.77 2.01 1.66
sp|P02763 Alpha-1-acid glycoprotein 1 1.31 0.50 0.02 11.70 9.38 7.24 5.40 0.81 0.82
sp|P01023 Alpha-2-macroglobulin 1.49 0.76 0.06 2.75 3.50 2.96 2.13 1.28 0.54
sp|P02787 Serotransferrin 2.73 0.59 0.03 10.67 12.47 10.19 4.70 0.82 0.33
sp|P01024 Complement C3 1.54 0.50 0.03 4.92 5.55 5.30 2.13 0.65 0.46
sp|P02647 Apolipoprotein A-I 2.36 1.20 0.03 8.79 15.56 7.59 6.03 0.37 0.29
sp|P31949 Protein S100-A11 1.25 9.73 14.59 18.03 23.99 20.14
sp|P61604 10 kDa heat shock protein, mitochondrial 0.54 0.90 1.04 2.38 1.92 3.77 1.26 1.00 0.44
sp|P30101 Protein disulfide-isomerase A3 1.71 3.10 1.32 13.18 2.11 16.29 2.42 9.82 5.70
sp|P14625 Endoplasmin 4.49 0.84 8.87 5.20 3.19 6.67 2.91 21.48 11.48
sp|Q9BY11 Protein kinase C and casein kinase substrate in
neurons protein 1
0.81 1.28 0.89 0.09 0.24 0.14 0.35 0.16 0.11
sp|Q13885 Tubulin beta-2A chain 1.34 0.67 0.77 0.05 0.11 0.06 0.36 0.19 0.31
sp|P17612 cAMP-dependent protein kinase catalytic
subunit alpha
0.90 1.14 1.46 0.49 0.55 0.06 0.52 0.61 0.62
sp|P63104 14-3-3 protein zeta/delta 1.07 0.70 1.46 0.25 0.18 0.13 0.53 0.53 0.38
sp|P61981 14-3-3 protein gamma 1.10 1.07 0.65 0.46 0.21 0.44 0.25 0.83 0.39
sp|P62258 14-3-3 protein epsilon 0.96 0.96 2.36 0.51 0.58 0.51 0.83 0.63 0.92
sp|Q92686 Neurogranin 1.42 0.72 2.31 0.21 0.03 0.37 0.27 0.02 0.02
sp|P31150 Rab GDP dissociation inhibitor alpha 0.96 0.72 2.36 0.16 0.52 0.10 0.38 0.19 0.23
sp|P62158 Calmodulin 1.31 0.85 2.42 0.25 0.04 0.18 0.15 0.34 0.06
sp|P62988 Ubiquitin 0.77 0.75 2.88 0.46 0.53 0.60 0.60 0.42 0.53
sp|P11142 Heat shock cognate 71 kDa protein 1.18 0.82 2.27 0.36 0.43 0.37 0.53 0.15 0.43
sp|P49773 Histidine triad nucleotide-binding protein 1 1.37 0.81 1.79 0.37 0.45 0.50 0.57 0.49 0.58
sp|P16949 Stathmin 1.13 1.05 2.27 0.74 0.37 0.64 0.17 0.18 0.65
sp|P12277 Creatine kinase B-type 0.89 0.86 5.65 0.04 0.26 0.04 0.21 0.15 0.85
sp|P04350 Tubulin beta-4 chain 0.96 0.68 1.87 0.08 0.26 0.09 0.67 0.27 0.07
sp|Q01813 6-phosphofructokinase type C 1.04 0.82 1.00 0.60 0.46 0.70 0.52 0.53 0.44
sp|Q13509 Tubulin beta-3 chain 0.96 0.79 0.21 0.11 0.10 0.09 0.35 0.30 0.32
sp|P09104 Gamma-enolase 0.68 0.44 1.50 0.05 0.07 0.04 0.16 0.10 0.07
sp|P04075 Fructose-bisphosphate aldolase A 0.78 0.63 1.09 0.50 0.25 0.51 0.17 0.61 0.30
sp|P09972 Fructose-bisphosphate aldolase C 0.83 0.67 1.08 0.08 0.44 0.05 0.23 0.14 0.14
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Table 1 List of differentially expressed proteins in GBM and non-malignant brain tissue samples (Continued)
sp|Q96JE9 Microtubule-associated protein 6 0.86 0.50 1.18 0.02 0.09 0.04 0.18 0.07 0.06
sp|P09936 Ubiquitin carboxyl-terminal hydrolase
isozyme L1
1.22 0.59 3.31 0.10 0.15 0.07 0.54 0.52 0.25
sp|P30086 Phosphatidylethanolamine-binding protein 1 1.07 0.42 2.25 0.22 0.24 0.19 0.30 0.07 0.03
sp|P10636 Isoform Tau-E of microtubule-associated
protein tau
1.32 0.60 1.56 0.09 0.45 0.05 0.39 0.02 0.03
sp|P00505 Aspartate aminotransferase, mitochondrial 0.68 0.96 0.34 0.14 0.70 0.21 0.44 0.12 0.08
sp|P00441 Superoxide dismutase [Cu-Zn] 1.32 0.55 0.94 0.18 0.59 0.11 0.76 0.31 0.35
sp|P21291 Cysteine and glycine-rich protein 1 1.80 0.66 3.22 0.26 0.22 0.41 1.06 0.09 0.56
sp|P07437 Tubulin beta chain 0.93 1.09 1.22 0.20 0.64 0.20 0.39 0.22 3.02
sp|P09543 2',3'-cyclic-nucleotide 3'-phosphodiesterase 1.10 0.28 1.32 0.07 0.26 0.09 2.03 0.07 0.03
sp|O76070 Gamma-synuclein 2.83 0.38 0.58 0.21 0.48 0.10 1.66 0.12 0.04
sp|Q99962 Endophilin-A1 0.80 0.70 0.52 0.21 0.58 0.15
sp|P38606 V-type proton ATPase catalytic subunit A 0.83 0.76 0.29 0.11 0.24 0.33
sp|Q99719 Septin-5 0.72 0.87 0.24 0.38 0.23 0.39
sp|P35611 Alpha-adducin 0.84 0.98 0.19 0.47 0.05 0.60
sp|P17174 Aspartate aminotransferase, cytoplasmic 1.03 0.82 1.51 0.65 0.88 0.59 0.80 0.19 0.08
Values shown in the table are the ratios for each of the proteins relative to its expression level in the designated individual non-malignant sample in each set.
Thus NB1, GBM1 and GBM2 are relative to NB2; NB4, GBM3 and GBM4 are relative to NB3 and NB5, GBM5 and GBM6 are relative to NB6. The missing values in
the table represent proteins that were either not detected in that set or not reliably quantified in iTRAQ experiments.
Figure 1 Verification of moesin and CD44 overexpression in GBMs. (A) Western blot analysis was carried out using specifics antibodies for
moesin, CD44, S100A11, 14-3-3ζ and γ-enolase and β-actin as described in Materials and Methods. Panel (i) shows increased expression of moesin
in GBM tissues (GBM1, GBM2 & GBM3) in comparison to non-malignant brain tissues (NB1 & NB4); (ii) CD44 overexpression in GBMs (GBM1 &
GBM3) as compared to non-malignant brain tissues (NB1 & NB4); (iii) S100A11 overexpression in all GBM tissues (GBM1, GBM2 & GBM3) in
comparison to non-malignant brain tissues (NB1 & NB4), whereas panels (iv) and (v) and (v) showed downregulation of γ-enolase and 14-3-3ζ
respectively in in GBM tissues as compared to non-malignant brain tissues, thereby verifying our iTRAQ results; (iii) β-actin was used as a loading
control; (B) Immunohistochemistry (IHC) was performed on independent set paraffin embedded sections of GBM tissues using monoclonal
antibodies (Moesin / CD44). IHC analysis showed strong membranous expression of (i) Moesin and (ii) CD44 in glioma cells. Arrows shows
membranous expression of moesin / CD44 in GBM tissue sections (Original magnification X400).
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http://www.molecular-cancer.com/content/12/1/74(i.e. width of the wound) was evaluated from 6 - 48 h. Our
results demonstrated increased cell migration (i.e. reduced
width of the wound) in both glioma cell lines, but not in
NHA upon treatment with HA (100 μg/mL, 48 h,
Figure 2A - 2D). No significant difference in the size of
the wound was observed in HA-treated glioma cells
(U87 / U373) in comparison to no treatment controls
until 24 h (Additional file 3: Figure S1A). Glioma cell
lines treated with TNF-α (10 nM, used as positive con-
trol in wound-healing assays) showed decrease in size of
the wound as early as 12 h (Additional file 3: Figure S1B).
Further, HA-treated cells and no treatment controls
demonstrated no significant difference in cell proliferation
(50 – 200 μg/mL, 24 – 48 h), as determined by MTTassay
(Additional file 4: Figure S2A). Moreover, treatment
with HA (100 μg/mL, 48 h) showed no difference in
percentage fraction of cells in each phase of the cellFigure 2 Effect of HA-treatment on cell migration. Glioma cells (U373 a
with HA (50 – 100 μg/mL) for 48 h. All HA-treatments were given in DMEM
cell migration when treated with HA (50 - 100 μg/mL) as compared to no
with HA (50 - 100 μg/mL) showed no significant difference as compared w
representing fold change ± standard deviation (S.D.) of the number of cells
controls (n = 3, *p < 0.05). (Original magnification X40).cycle in glioma cell lines in comparison to no treatment
controls (Additional file 4: Figure S2B).
Effect of HA-treatment on CD44 and moesin in glioma
cells
To determine the expression levels of HA-receptor,
CD44 and ERM protein, moesin, in NHA and glioma
cell lines (U87 / U373), we carried out Western blot ana-
lysis. Our results demonstrated overexpression of both
CD44 and moesin in both glioma cell lines as compared
to NHA (Figure 3A). To determine the effect of HA-
treatment on expression of CD44 and moesin, U373 /
U87 cells were treated with HA at dose (50 – 100 μg/mL)
for 24 – 48 h. Western blot analysis showed no significant
change in expression of either moesin or CD44 in glioma
cells (U87 / U373) on treatment with HA (Figure 3B).
Notably, confocal laser scan microscopy revealed increasend U87) and normal human astrocytes (NHA) were plated and treated
only. Both glioma cell lines (A) U373 and (B) U87 showed increase
treatment controls (NTC); (C) Normal human astrocytes (NHA) treated
ith no treatment control (NTC). Panel (D) shows bar graph
in the wound for on HA-treatment as compared to no treatment
Figure 3 Effect of HA-treatment on moesin and CD44 in glioma
cells (U373 / U87). (A) Panel shows western blot analysis
demonstrating increased expression of both (i) moesin and (ii)
CD44 in glioma cells (U87 and U373) as compared to NHA; (B) Effect
of HA-treatment on moesin and CD44 expression was determined
using Western blotting. No significant difference in expression of
either (i) moesin, or (ii) CD44 was observed on treatment with HA
in a dose dependent manner (50 - 100 μg/mL) for 24 - 48 h.
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in HA-treated glioma cells in comparison to no treatment
controls, suggesting HA-induced moesin-CD44 inter-
action in glioma cells may be responsible for increase in
migratory cells (Figure 4A and 4B). This prompted us to
further investigate the role of moesin in HA-induced
cell migration in gliomas in the context of CD44-HA
interaction.
HA-treatment induces CD44-moesin interaction in glioma
cells
To confirm the interaction of CD44 with moesin on HA-
treatment, we performed co-IP assays with antibodies spe-
cific for CD44 / moesin using whole cell lysates obtained
from glioma cells (U87 / U373) treated with either tumor
necrosis factor-α (TNF-α, 10 nM for 24 h) or HA (100 μg/
mL, 48 h), and no treatment control (NTC). Immunopre-
cipitation using CD44 antibody, followed by Western blot
analysis with moesin antibody, revealed a single band
(~72 kDa) that corresponded with the expected size for
moesin in CD44 immunoprecipitates from both HA
treated cell lines (Figure 4B). No such band was observed
in untreated controls, suggesting that the interaction of
moesin with CD44 was in response to HA treatment. Gli-
oma cells treated with TNFα positive control) also showed
a strong band for moesin (Figure 4B). No band corre-
sponding to moesin was observed in negative controls,wherein immunoprecipitation was performed on lysates
from HA-treated cells either without antibody or isotype
mouse IgG (Figure 4B). These results were further con-
firmed using reverse immunoprecipitation assays. Moesin-
immunoprecipitates obtained from both U87 and U373
cell lines treated either with HA (100 μg/ml, 48 h) or
TNF α (10 nM, 24 h) and untreated controls. In all in-
stances where the immunoprecipitates were obtained
from HA- / TNF α treated cells, a band of CD44 was
observed in lanes (Figure 4B). No band of CD44 was ob-
served in immunoblots in lanes corresponding to the
negative controls (Figure 4B). This clearly demonstrated
an important role of moesin downstream of HA-CD44
interaction in glioma cells.
Role of moesin in HA-induced cell migration in glioma
cells
U87 and U373 cells were transfected with either siRNA
targeting moesin or negative control scrambled siRNA.
Western blot analysis of the cell lysates showed down-
regulation (>70%) of moesin expression in both cell
lines (U87 / U373) transfected with moesin siRNA in
comparison to no treatment and negative control cells
(Figure 5A). Notably, glioma cells showing lower ex-
pression of moesin also showed reduced cell migration
in wound-healing assays as compared to no transfection
controls (Figure 5B). Furthermore, to demonstrate the
role of moesin in HA-induced cell migration, both
glioma cell lines were transfected with moesin siRNA
followed by treatment with HA (100 μg/mL) for 48 h.
Wound-healing assay of these siRNA transfected and
HA treated cells showed reduced cell migration relative
to the no treatment control cells, demonstrating the sig-
nificance of moesin in HA-induced cell migration in
GBM cells (Figure 5B).
These results were further verified using transwell mi-
gration assays. Both glioma cell lines (U87 and U373)
transfected with siRNA targeting moesin, resulting in its
reduced expression, demonstrated significantly lower mi-
gration from the upper chamber to the lower chamber as
compared to no transfection controls. Similar results were
observed in glioma cells transfected with siRNA targeting
moesin followed by HA-treatment, in comparison to no
transfections controls and cells transfected with scrambled
siRNA when treated with HA (Figure 5C).
Discussion
In this study, we used multidimensional LC-MS/MS
analysis for identification of differentially expressed pro-
teins labeled with isobaric mass tags (iTRAQ) in clinical
samples of GBM relative to non-malignant brain tissues.
Our study led to the identification of 57 differentially
expressed proteins of which 23 were upregulated and 34
downregulated in GBM tissues. Interestingly, stem cell
Figure 4 HA-treatment induces CD44-moesin interaction. (A) Both U373 and U87 cells were plated on coverslips and treated with HA
(100 μg/mL, 24 h) followed by fixation and labeling with moesin and CD44 monoclonal antibodies as described in Materials and Methods. Panel
shows images obtained using confocal laser scan microscopy (CLSM) representing localization of moesin (rhodamine, red) and CD44 (FITC, green)
in glioma cell lines (a) U373 and (b) U87 in (i) no treatment controls (NTC) and (ii) HA-treated glioma cells. Arrows show membranous co-
localization of moesin and CD44 in glioma cells (U373 / U87) (original magnification X600); (B) Co-IP assays for moesin / CD44 was performed
using whole cell lysates obtained from HA (100 μg/mL, 48 h) or TNF-α (10 nM, 24 h) treated or no treatment control glioma cells (U373 / U87)
using respective antibodies to determine moesin-CD44 interactions. Panel represents immunoblot (IB) of moesin showing a single band (~72 kDa,
moesin) in CD44 immunoprecipitates (IP) obtained from HA-treated or TNF-α treated glioma cells (U87 / U373) and whole cell lysates (WCL of
U373 cells) used as positive controls. No band of moesin was observed in negative controls, wherein pull-down was carried out using beads only
or isotype mouse IgG. Similarly, moesin-immunoprecipitates showed a single band of CD44 in HA treated or TNF-α treated glioma cells
(U87 / U373) and whole cell lysates (U373 cells, input used as a positive control).
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Figure 5 Role of moesin in HA-induced migration in glioma cells. (A) Western blot analysis. Both the glioma cell lines (U87 and U373) were
transfected with siRNA targeting moesin and scrambled siRNA used as a negative control for 48 h followed by Western blotting. Panel represents
shows effective downregulation (>70%) of moesin in both U87 and U373 cells in 48 h as compared with no transfection controls (NTC). Cells
transfected with scrambled siRNA showed no significant change in the expression of moesin. β-actin was used as a loading control in western
blot; (B) Glioma cells (U373 and U87) were transfected with moesin siRNA (200 nM) followed by treatment HA (100 μg/mL,48 h) and analyzed
using wound healing assay as described in Materials and Methods. Panel shows number of cells migrating in the wound (i) no treatment
controls (NTC); (ii) HA treatment (100 μg/mL, 48 h); (iii) cells transfected with moesin siRNA (200 nM, 48 h); (iv) cells transfected with moesin
siRNA followed by treatment with HA (Original magnification X40). (C) Bar graph showing relative percentage of glioma cells (U373 / U87) that
migrated into the lower chamber of transwell plates in no treatment controls (NTC), glioma cells treated with HA only, cells transfected with
moesin siRNA (i.e. the cells with reduced moesin expression) and glioma cells transfected with siRNA targeting moesin followed by treatment
with HA. As shown in the graph, glioma cells showing reduced expression of moesin demonstrated significantly reduced migration in transwell
chambers even after treatment with HA (n = 3, *p-value < 0.01). This clearly demonstrates the significance of moesin downstream of HA-CD44
interaction in glioma cells.
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moesin) and calcium binding proteins of the S100 family
(S100A11 & S100A6) were upregulated in GBM tissues.
Three of the seven isoforms of the 14-3-3 family, 14-3-3
zeta, gamma and epsilon, and metabolic enzymes such
as gamma enolase were downregulated in GBM tissues
as compared to non-malignant brain tissues.
Significantly, knockdown of moesin alone among ERM
family of proteins reduced migration of GBM cells.
Moesin belongs to the ERM (ezrin, radixin, moesin)
family of proteins that functions as molecular cross-
linkers between plasma membrane and cytoplasmic actin
filaments [15,17,18]. ERM proteins are actively involved
in actin cytoskeleton reorganization in response to sev-
eral growth stimuli and serve as substrates for growth
factor receptors including CD44, CD43, E-cadherin and
intercellular adhesion molecule (ICAM-1, ICAM-2 and
ICAM-3) [15]. ERM proteins are required for the forma-
tion of focal adhesion complexes and stress fibers down-
stream of Rho-GTPase activation. Knocking down the
expression of ERM proteins using anti-sense oligonucle-
otides or siRNA affects cell-cell and cell-matrix adhesion
[15,17,18]. Notably, ezrin and radixin, the other mem-
bers of the ERM family, showed no significant differen-
tial expression in GBM and normal brain tissues as
revealed by our iTRAQ analysis.
Overexpression of CD44, a transmembrane glycopro-
tein, has been reported in glioblastoma, breast, prostate,
cervical, ovarian and head and neck cancer [19-23]. CD44
overexpression is responsible for increased survival, prolif-
eration, migration, invasion and metastasis leading to poor
prognosis among cancer patients [19-23]. Our study re-
veals overexpression of CD44 is also true in GBM and that
it is localized to the membrane. CD44 serves as a major re-
ceptor for hyaluronan (HA), a polysaccharide that forms
an important component of extracellular matrix (ECM)
[15,16]. The levels of HA and its receptor CD44 in tumor
cells are predictive of malignancy and often correlate with
cancer aggressiveness in patients with glioblastoma, breast,
prostate and non-small cell lung cancers [15,16,19-23].HA-CD44 interaction potentially mediates the activa-
tion of ankyrin and Rho GTPase in ovarian and breast
cancer cells [24,25]. CD44-EGFR interaction in glioblast-
oma cells enhanced HA-mediated phosphorylation of
extracellular signal regulated kinases 1 and 2 (ERK1 and
ERK2). HA treatment activates and promotes EGFR-
mediated pathways including Ras, RhoA, Rho kinase,
and phosphatidylinositol-3 (PI-3) kinase signaling in
head and neck cancer [26-28]. The CD44-EGFR complex
also associates with leukemia-associated Rho-guanine
(LARG) nucleotide exchange factor activating down-
stream signaling through ras and RhoA [26-30]. Recent
studies also revealed CD44 overexpression potentiates
the migration and invasion of breast cancer cells and
promotes metastasis to the liver through CD44–HA /
NFκB / cortactin signaling pathway [31]. Our results also
demonstrate increased migration in response to HA-
treatment in glioma cells lines. However, the down-
stream targets underlying HA-CD44 interaction leading
to increased migration and invasion in glioblastoma cells
remain unidentified.
HA-induced CD44-moesin interaction resulted in in-
creased cell migration, while knockdown of moesin re-
duced migration of GBM cells, even in cells treated with
HA. This indicates that HA-induced CD44-moesin inter-
action contributes to increased migration in GBM cells. In
support of our hypothesis, Hirao et al., [32] demonstrated
that the cytoplasmic domain of mouse recombinant CD44
has a very weak binding activity to any of the ERM pro-
teins at physiological ionic strength, but that the presence
of phosphatidylinositol-4,5-bisphosphate (4,5-PIP2) causes
it to bind ERM proteins with high affinity. This interaction
results in an increase in the number of actin filament-
association sites on the cytoplasmic surface of plasma
membranes. This data supports our results demonstrating
co-localization of CD44-moesin on advancing edges of
plasma membrane in HA-treated glioblastoma cells. In
addition, Rho-GDP dissociation inhibitor (GDI), a regula-
tor of a small GTP binding protein Rho, also plays an im-
portant role in formation of the CD44 / moesin complex
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ERM complex formation provides an increasing number
of actin filament attachment sites on the cytoplasmic sur-
face of plasma membranes at microvilli, cleavage furrows,
ruffling membranes, and cell-cell / cell-matrix adhesion
sites [32].
Conclusions
Our mass spectrometry-based analysis of GBM and non-
malignant brain tissues yields insight into the differential
expression of proteins involved in migration and inva-
sion of glioblastoma cells. We show that the significant
role of CD44-moesin interaction in cellular migration is
in response to hyaluronan, an important component of
the tumor microenvironment. Our results suggest that
development of inhibitors which interfere with CD44-
moesin interactions may provide a means to counteracting
cellular migration in gliomas.
Methods
Tissue processing and iTRAQ labelling
Flash-frozen human GBM operative samples, non-
malignant brain tissues (n = 6 each) and paraffin-
embedded GBM tissues sections were obtained from the
University of Toronto, Nervous System Tumor bank, in
accordance with Research Ethics Board guidelines and
consent. Six tissue samples, each of GBM and non-
malignant brain (NB), were washed thrice in 1 mL of cold
phosphate buffered saline (PBS, 0.1 M, pH= 7.2) and ho-
mogenized in 0.5 mL of PBS with a cocktail of protease in-
hibitors (1 mM 4-(2-aminoethyl) benzenesulfonyl fluoride,
10 μM leupeptin, 1 μg/mL aprotinin and 1 μM pepstatin),
centrifuged and the supernatant was collected. The total
protein concentration was determined using a Bradford-
type colorimetric assay as described earlier [7-11]. For each
set, clarified sample lysates were individually denatured,
alkylated, digested with trypsin and labeled with iTRAQ
labels. The labeled samples were then pooled to form three
4-plex iTRAQ sets (see Additional file 1:Table S1). Each
iTRAQ set was processed by offline two-dimensional LC-
MS/MS analysis as described earlier [7-11].
Mass spectrometry and data analysis
Tandem MS analysis was performed on a QSTAR Pulsar
(Applied Biosystems Inc/ MDS Analytical) instrument in
information dependent acquisition (IDA) mode using
Analyst QS version 1.1 (Applied Biosystems Inc) as de-
scribed [7-11]. Data from each set of fractions were col-
lectively searched against a database downloaded from
Uniprot (download date: 2nd June 2010) that contained
34950 protein sequences, using ProteinPilot version 4.0
(Applied Biosystems). Besides matching spectra with
sequences, ProteinPilot also features a grouping function
that minimizes the redundancy between the proteinsreported. Proteins reported herein are, therefore, only
those for which an unshared peptide or group of peptides
were detected. To provide a measure of confidence in the
proteins reported, the database against which the mass
spectrometric data was searched included a decoy data-
base generated by reversing the protein sequences in the
original database and concatenating this reverse database
to the original database. Any proteins matching the re-
verse sequence are obviously false, thereby providing a
basis for calculation of the false discovery rate (FDR). This
FDR calculation was described in Tang et al., [33].
Relative quantification of proteins, which was simul-
taneously performed by ProteinPilot, was based on the
areas of the iTRAQ signature ion peaks. Only peptides
not shared with other reported protein (or group) con-
tribute to the overall ratios reported for the protein. The
overall protein ratios reported is a weighted average of
the ratios of the contributing unique peptides, where the
weighting factor is determined by the % error of the in-
dividual peptide ratios. Further, the reported ratios were
normalized using a factor, termed the applied bias that
is calculated based on the assumption that the majority
of the proteins being compared between the samples in
a set are expressed at similar levels [34].
Protein alignment
To minimize redundancy between proteins reported in
the three individual iTRAQ sets and to ensure consistency
of reported isoforms from one set to the next, the results
of the three sets were aligned using an Excel based Protein
Alignment Template (an early version of which was kindly
provided by Dr. Sean Seymour, AB SCIEX) [35]. A master
list of all the proteins identified in this study was first
generated by performing a search on the combined data
from all three iTRAQ sets and duplicate runs using
ProteinPilot. The Protein summaries from the ProteinPilot
results for the individual sets were then imported into the
template and the proteins were collated using the master
list as the reference. The complete list and the individual
ratios for each protein in each set are shown in Additional
file 2: Table S2.
Western blotting
Equal amounts of whole cell lysates from GBM (n = 3)
and non-malignant brain tissues (n = 2) as used in
iTRAQ analysis were subjected to Western blotting [36].
Briefly, equal amounts of proteins (50 μg) obtained from
GBM, non-malignant brain tissues and glioma cells were
resolved on sodium dodecyl sulphate - polyacrylamide gels
(SDS-PAGE). The proteins were then electro-transferred
onto nitrocellulose membranes (BioRad, Hercules, CA).
After blocking with 5% non-fat powdered milk in Tris-
buffered saline (TBS, 0.1 M, pH= 7.4), blots were
incubated with mouse monoclonal anti-moesin (cat no.
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(cat no. ab123020), rabbit monoclonal anti-CD44 (cat no.
ab51037) / rabbit polyclonal 14-3-3ζ (cat no. sc1019) /
anti-S100A11 (cat no. sc-98427) antibody at 4°C over-
night. Membranes were incubated with secondary anti-
body, HRP-conjugated / rabbit / mouse anti-IgG (BioRad,
CA), diluted at an appropriate dilution in 1% bovine
serum albumin (BSA), for 2 h at room temperature. After
each step, blots were washed three times with Tween
(0.1%) -Tris-buffer saline (TTBS). Protein bands were
detected by the enhanced chemiluminescence method
(GE Health Care) on Kodak Hyperfilm.
Immunohistochemistry of moesin and CD44 in GBM tissues
Immunohistochemistry for moesin and CD44 were carried
out in independent set of paraffin embedded sections of
GBM in tissue microarray format (TMA) as described
earlier [37]. In brief, the sections were deparaffinized in
xylene, hydrated in gradient alcohol, and pre-treated in a
microwave oven for 15 min at maximum power in citrate
buffer (0.01 M, pH= 6.0, 0.05% Tween-20) for antigen re-
trieval. The sections were incubated with hydrogen perox-
ide (0.3% v/v) in phosphate buffered saline (PBS, 0.1 M,
pH= 7.2) for 15 min to quench the endogenous peroxid-
ase activity, followed by blocking with 5% BSA to preclude
non-specific binding. Thereafter, the slides were incubated
with mouse monoclonal anti-moesin antibody / rabbit
monoclonal anti-CD44 for 16 h at 4°C. The primary anti-
body was detected using the streptavidin-biotin complex
with the Dako LSAB plus kit (Dako Cytomation,
Glostrup, Denmark) and diaminobenzidine as chromo-
gen [10,13,37]. All procedures were carried out at room
temperature unless otherwise specified. Slides were
washed three times using PBS containing 0.025%
Triton-X-100, after every step. Finally, the sections were
counterstained with Mayer’s hematoxylin and mounted
with DPX mountant. In the negative control tissue
sections, the primary antibody was replaced by isotype
specific non-immune mouse IgG. The sections were
evaluated by light microscopic examination.
Cell culture, treatment with HA and siRNA transfections
GBM cells (U87 and U373) and normal human astro-
cytes (NHA) immortalized with human telomerase con-
struct (hTERT) were a kind gift from Dr. Abhijit Guha,
The Hospital for Sick Children, University of Toronto,
Toronto, Ontario. Cells were grown in monolayer cul-
tures in Dulbecco’s modified eagle medium (DMEM)
(Sigma, St. Louis, MO) supplemented with 10% FBS,
1 mM L-glutamine, 1 mM minimum essential medium
(MEM), 100 μg/mL streptomycin and 100 U/mL penicil-
lin in a humidified incubator (5% carbon-dioxide, 95%
air) at 37°C as described earlier [11,36]. Both the GBM
cell lines and NHA cells were treated with HA (SigmaSt. Louis, MO) at dose range (50 - 200 μg/mL) for 6 -
48 h. For all experiments, HA was suspended in the
growth medium, i.e. DMEM only without FBS. Effect of
treatment on cell migration, proliferation, cell cycle and
expression of moesin, CD44 was determined as de-
scribed below. Pre-validated siRNA targeting moesin
was obtained from Ambion (Life Technologies, CA).
Negative control siRNA showing no homology to any of
the known mammalian gene (i.e., having a scrambled
sequence) and Cy3-labeled control siRNA for determin-
ing transfection efficiency were also obtained from
Ambion (Life Technologies, CA). Transient transfection
of siRNAs was performed using Lipofectamine 2000 and
cells were collected after 48 h post-transfection for fur-
ther Western blot analyses as described earlier [11,36].
Wound-healing and cell migration assays
For wound-healing assays, 1×106 GBM cells (U87 /
U373) or NHA cells were plated in 6-well plates for
24 h. Cells were either left untreated (no treatment con-
trols), treated with HA (50 - 100 μg/mL) suspended in
DMEM only or transfected with siRNA targeting moesin
(200 nM, 24 - 72 h). Further, to determine the role of
moesin downstream of HA - CD44 induced cell migra-
tion, glioma cells were transfected with moesin siRNA
followed by treatment HA (100 μg/mL) for another 48 h.
Similar-sized wounds were created in monolayer cells by
scraping a gap using a micropipette tip either before treat-
ment with HA or 24 h after siRNA transfections. After re-
moving cell debris by rinsing with phosphate-buffered
saline, fresh medium was added, and the cells started mi-
grating from the edge of the wound and repopulated the
gap area. Cells were then observed for ‘wound closure’
under a light microscope after 6 – 48 h and the number of
cells were counted in the wound for quantitative analysis
among treated cells and no treatment controls.
Further these results were verified by carrying out mi-
gration assays performed using gelatin-coated polycar-
bonate filters (pore size, 8 μm) on transwells separating
the upper and lower chamber of 24-well plates (BD Bio-
Sciences). Chemotaxis medium (DMEM with 0.5% BSA
and 10 mM HEPES) was added to the bottom chamber.
siRNA transfected, HA-treated or no transfection control
cells (1 × 105 / well) suspended in DMEM containing ei-
ther HA (100 μg/mL) or DMEM only used as no treat-
ment controls (NTC) were placed in the upper chamber.
The plates were incubated at 37°C overnight. Viable cells
in the lower chamber were collected and counted [11].
Cell proliferation assay
Glioma cells (U87 / U373) were plated in triplicates in 96 -
well plates in complete medium (i.e. DMEM containing
10% FBS). The cells were cultured overnight and then ei-
ther treated with HA (50 – 200 μg/mL) in DMEM only,
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on cell proliferation. Cell proliferation was measured by
adding MTT at 37°C for 3 - 4 h. The formazan crystals
were dissolved in 100 μl of dimethylsulphoxide (DMSO)
and the optical density (OD) was measured at a wave-
length of 570 nm as described earlier [36].
Cell-cycle analysis using flow cytometry
HA-treated (100 μg/mL) or untreated no treatment con-
trol glioma cells (U87 / U373) were collected and
centrifuged to collect non-adherent cells. Adherent cells
were washed with phosphate buffered saline (PBS, pH =
7.4) and trypsinized. Both non-adherent and adherent cell
populations were pooled for further analysis. Cells were
fixed in 70% ethanol and resuspended in buffer containing
PBS (pH = 7.4), EDTA (0.5 M, pH= 8.0), Triton X-100
(0.05%), RNAse A (50 μg/ml) and propidium iodide (PI,
100 μg/ml) before flow cytometry analysis. The PI-labeled
cells were analyzed using a BD Canto flow cytometer and
the output thus obtained was analyzed using the BD Cell
Quest Pro software as described earlier [36]. Cells were
gated to exclude cell debris and cell clumps.
Co-immunoprecipitation (co-IP) assays
Co-immunoprecipitation assays to determine CD44 -
moesin interactions were carried out using specific anti-
bodies (CD44 / moesin) and analyzed by Western blotting
as described earlier [37]. Briefly, GBM cells (U87 / U373)
treated with either HA (100 μg/mL, 48 h) or (TNF-α, 10
nM, 24 h) and no treatment control cells were rinsed in
ice-cold PBS and lysed in IP lysis buffer [38]. Lysates
were incubated on ice for 30 min. and cell debris was
removed by centrifugation. Lysates were pre-cleared by
adding 20 μL of Protein A agarose (Santa Cruz Biotech.,
Santa Cruz, CA), followed by overnight incubation with
specific antibodies (CD44 / moesin) on a rocker at 4°C.
Immunocomplexes were pulled down by incubating with
Protein A-agarose for 2 h at 4°C, followed by washing
with 1X ice-cold lysis buffer to eliminate non-specific in-
teractions. Protein A-agrose-bound immunocomplexes
were then resuspended in Laemelli sample buffer (1X),
boiled for 5 min. and analyzed by Western blotting. In
addition, glioma cells treated with tumor necrosis factor-
α (TNF-α) were used as a positive control for co-IP ex-
periments [37]. In negative controls, primary antibodies
used for co-IP was replaced by isotype IgG controls [37].
Statistical analysis
Each experiment was repeated at least twice or was
performed in triplicates. Significance of the difference
between two measurements was determined using Stu-
dents t-test; p-value < 0.05 was considered as significant
[11,36]. Numerical data are represented as the mean ±
standard deviation.Additional files
Additional file 1. Experimental design for iTRAQ labeling of tissue
samples.
Additional file 2. Complete results showing protein identifications
and ratios.
Additional file 3: Figure S1. Effect of HA-treatment on cell migration.
Glioma cells (U373 and U87) were plated and treated with HA (100 μg/
mL) or TNF-α (10 nM) for 6 - 24 h. All HA- / TNF-α treatments were
given in DMEM only. Panel (A) shows no significant reduction in
wound or number of cells in wound in either of the glioma cell lines (i)
U373 and (ii) U87 when treated with HA (100 μg/mL) for 6 – 24 h as
compared to no treatment controls (NTC); Panel shows data for (i) NTC;
(ii)12 h and (iii) 24 h treatment; Panel (B) shows a significant reduction
in wound and increase in num ber of cells in the wound of U87 cells
treated with TNF-α (10 nM) as early as 12 h. Treatment with TNF-α (10
nM) served as positive control for wound healing assays (Original
magnification X40).
Additional file 4: Figure S2. (A) Cell viability assay. To determine the
effect of HA-treatment on cell proliferation, GBM cells (U87 / U373) were
plated in triplicates in 96-well plates in complete medium followed by
treatment with varying concentrations of hyaluronan (HA) in DMEM
only for 24 - 48 h. Panel A shows no significant difference in cell
proliferation in glioma cells (U373 & U87) on treatment with HA (50 -
200 μg/mL) for 24 - 48 h; (B) Cell Cycle Analysis. For cell cycle analysis,
both HA-treated and untreated no treatment control cells were
collected, fixed and suspended in FACS buffer as described in Materials
And Methods section. Panel B shows no significant difference in cell
cycle in glioma cells (U373 & U87) on treatment with HA (100 μg/mL)
for 48 h.
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